These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23276932)

  • 1. Prognostic significance and targeting of HER family in colorectal cancer.
    Khelwatty SA; Essapen S; Seddon AM; Modjtahedi H
    Front Biosci (Landmark Ed); 2013 Jan; 18(2):394-421. PubMed ID: 23276932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
    Ng K; Zhu AX
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):8-20. PubMed ID: 18006328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies in the treatment of advanced colorectal cancer.
    Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
    Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.
    Hu S; Fu W; Xu W; Yang Y; Cruz M; Berezov SD; Jorissen D; Takeda H; Zhu W
    Cancer Res; 2015 Jan; 75(1):159-70. PubMed ID: 25371409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
    Snyder LC; Astsaturov I; Weiner LM
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
    Khelwatty SA; Essapen S; Seddon AM; Fan Z; Modjtahedi H
    Br J Cancer; 2015 Sep; 113(7):1010-9. PubMed ID: 26372697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of targeted therapy in the treatment of advanced colorectal cancer.
    Fakih M
    Curr Treat Options Oncol; 2008 Dec; 9(4-6):357-74. PubMed ID: 19238551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
    Montagut C; Dalmases A; Bellosillo B; Crespo M; Pairet S; Iglesias M; Salido M; Gallen M; Marsters S; Tsai SP; Minoche A; Seshagiri S; Serrano S; Himmelbauer H; Bellmunt J; Rovira A; Settleman J; Bosch F; Albanell J
    Nat Med; 2012 Jan; 18(2):221-3. PubMed ID: 22270724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
    Martinelli E; De Palma R; Orditura M; De Vita F; Ciardiello F
    Clin Exp Immunol; 2009 Oct; 158(1):1-9. PubMed ID: 19737224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
    Jackson C; Cunningham D
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S8-15. PubMed ID: 18361806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
    Reidy DL; Vakiani E; Fakih MG; Saif MW; Hecht JR; Goodman-Davis N; Hollywood E; Shia J; Schwartz J; Chandrawansa K; Dontabhaktuni A; Youssoufian H; Solit DB; Saltz LB
    J Clin Oncol; 2010 Sep; 28(27):4240-6. PubMed ID: 20713879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
    Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
    Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
    Gainet M; Guardiola E; Dufresne A; Pivot X
    Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.